Compare Tidewater Inc (TDW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs Twist Bioscience Corp — how do they compare? Tidewater Inc trades at $85.16 (market cap $4.21B), while Twist Bioscience Corp trades at $165.06 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.4× Tidewater Inc's market cap, and Tidewater Inc is more actively traded (590,005 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 25 Days and Twist Bioscience Corp for 27 Days on average.
| TDW | TWST | |
|---|---|---|
Market Cap | $4.21B | $10.08B |
Volume | 590,005 | 4,229,037 |
Sector | Energy | Health |
52-Week High | $100.61 | $205.00 |
52-Week Low | $47.29 | $25.45 |
Typical Hold Time | 25 Days | 27 Days |
Enterprise Value | $4.25B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $83.40, up 1.62% on the day, with a bullish technical signal driven by moving averages. Recent earnings showed a Q2 2026 beat but misses in Q1 and Q2 relative to expectations, while the company completed the Wilson Sons Ultratug acquisition in August 2026, signaling growth initiatives. Key financials include a P/E of 17.18 and net income margin of 18.34% for 2025, though 2026 projections indicate lower revenue and profitability.
The outlook is mixed, with analyst consensus leaning toward a buy rating and a price target of $105.50 offering upside potential, but risks include earnings volatility, competitive pressures in the energy sector, and macroeconomic headwinds affecting day rates and utilization.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
